Please login to the form below

Not currently logged in
Email:
Password:

ViiV Healthcare

This page shows the latest ViiV Healthcare news and features for those working in and with pharma, biotech and healthcare.

Gilead and ViiV among winners at PM Society Digital Awards

Gilead and ViiV among winners at PM Society Digital Awards

Gilead and ViiV among winners at PM Society Digital Awards. First 'Pharma Digital Partner' award presented. ... Meanwhile ViiV Healthcare, Teva and Celgene all took a Gold and a Silver.

Latest news

  • Gilead’s Biktarvy gets European approval, setting up battle with GSK Gilead’s Biktarvy gets European approval, setting up battle with GSK

    Juluca, marketed by GSK-led ViiV Healthcare is a two-drug combination which received EU approval just last month, putting the companies into direct competition.

  • GSK’s vaccines president Debruyne heads for the exit GSK’s vaccines president Debruyne heads for the exit

    GSK’s vaccines outlet grew by 6% last year, a significant amount compared to its pharma and consumer healthcare businesses, which saw growths of 3% and 2% respectively. ... along with vaccines chairman Moncef Slaoui and ViiV Healthcare’s - GSK’s HIV

  • ViiV’s two-drug HIV combo backed by CHMP ViiV’s two-drug HIV combo backed by CHMP

    ViiV’ s two-drug HIV combo backed by CHMP. The committee also backs two biosimilar medicines. ... ViiV Healthcare’s dual HIV therapy Juluca has been given a green light by the EMA’s Committee for Medicinal Products for Human Use (CHMP), setting up

  • Gilead says switching studies back new HIV therapy Biktarvy Gilead says switching studies back new HIV therapy Biktarvy

    share for ViiV, so Gilead will have to pull out all the stops to build momentum behind its new drug. ... GSK alleges that Gilead’s HIV integrase inhibitor bictegravir infringes on patents held by ViiV on dolutegravir, and it wants to receive royalties

  • Gilead’s triple HIV drug approval prompts GSK lawsuit Gilead’s triple HIV drug approval prompts GSK lawsuit

    Gilead’ s triple HIV drug approval prompts GSK lawsuit. ViiV claims bictegravir infringes its patent estate. ... GSK’s ViiV Healthcare unit has filed a lawsuit against Gilead claiming that its integrase inhibitor bictegravir - which is one of the

More from news
Approximately 21 fully matching, plus 58 partially matching documents found.

Latest Intelligence

  • The race for an HIV ‘cure’ The race for an HIV ‘cure’

    GSK’s majority-owned ViiV Healthcare is the strongest challenger to Gilead’s 52% market share. ... Gilead runs a Test and Treatment scheme in Tanzania in collaboration with The Vatican, whose locally-based nurses are trusted to deliver the HIV

  • Pharma deals during October 2012 Pharma deals during October 2012

    The first is the revised deal between ViiV Healthcare (the speciality HIV company formed by GSK and Pfizer in 2009) and Shionogi. ... Under the new agreement, ViiV Healthcare will acquire the exclusive global rights to the assets in the Shionogi-ViiV

  • Shionogi: an expanding commercial focus Shionogi: an expanding commercial focus

    The candidate the company is most excited about is the nce-daily HIV integrase inhibitor dolutegravir, which Shionogi is co-developing with the Pfizer and GlaxoSmithKline's ViiV Healthcare venture. ... Establishes Shionogi-GlaxoSmithKline joint venture

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 1 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Ashfield to present at eyeforpharma’s Patient Summit Europe 2016, London, UK

    Real world case examples from our panel of experts from industry, advocacy groups and the healthcare profession. ... Our speakers will be joined by Dr Oleksandr Gorbenko, Global Patient Affairs Medical Lead, ViiV Healthcare, and Flóra Raffai, Executive

  • Ashfield walks away with gold at EVCOM Clarion Awards

    Ashfield won the top prize in the Conference (Screen) category for ‘ A vision for the future: an AIDS-free generation’, the first in an emotive series for ViiV Healthcare which shares ... However, this entire project would not have been possible

  • PharmiWeb Solutions

    PM Society Digital Awards 2016 - Silver Award for HCP Education and Support in partnership with ViiV Healthcare. ... Eyeforpharma Barcelona Finalist 2016 - Most valuable HCP or Healthcare initiative in partnership with ViiV Healthcare.

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M3 (EU)

M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics